Abeona Therapeutics to Present at UBS 2016 Global Healthcare Conference

Company CEO to Present on Wednesday, May 25th at 11:30 am ET

NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/23/16 --

Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President and CEO, Tim Miller, PhD, will be presenting for the company at the UBS 2016 Global Healthcare Conference in New York City, NY on Wednesday, May 25th at 11:30am ET. The presentation will be webcast live and can be accessed through the following URL: https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=92_LUN46NN

The following are the specific details regarding Abeona Therapeutics Presentation:

Event: UBS 2016 Global Healthcare Conference
Date: Wednesday, May 25th 2016
Time: 11:30 am ET
Location: New York City, NY
Room: Ballroom V, Uris
Webcast Link: https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=92_LUN46NN

Abeona Therapeutics Inc announced last week that the first patient had been dosed in its Phase 1/2 trial for ABO-102 (AAV-SGSH), a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A (Mucopolysaccharidosis Type IIIA or MPS IIIA).

"Abeona is committed to building a leadership position in the development of promising gene therapies for children with rare diseases," state Steven H. Rouhandeh, Executive Chairman. "We believe our gene therapy technique, delivering a single intravenous injection to treat the whole body as well as CNS, represents a new approach to address the relentless progress of Sanfilippo syndrome."

About Abeona:

Abeona Therapeutics Inc. develops and delivers gene therapy and plasma-based products for severe and life- threatening rare diseases. Abeona's lead programs are ABO-101 (AAV-NAGLU) and ABO-102 (AAV-SGSH),

adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). The company is also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV- FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contact:

Andre'a Lucca
Vice President, Communications & Operations
Abeona Therapeutics Inc
+1 (212)-786-6208

Christine Berni-Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc
+1 (212)-786-6212

Source: Abeona Therapeutics